As predicted, the combined treatment of BRAF PTEN mice with AZD6244/AZD8186 was highly effective, resulting in attenuated tumor growth, tumor regression over the first 7 days of treatment, and extended overall survival (Fig. 5B). This evidence concerns the gene BRAF and neoplasm.